Elimination of Acquired Factor VIII Antibodies by Extracorporal Antibody-based Immunoadsorption (Ig-Therasorb®)

Summary

Treatment of potent factor VIII antibodies is a difficult problem. In some cases a reduction ofthe antibody titer is necessary for effective treatment with human factor VIII concentrates. We describe a new method for extracorporal eliminationof factor VIII antibodies (antibody-based immunoadsorption). Blood is drawn from an antecubital vein, citrated, and plasma is separated with a rotating membrane. Plasma passes alternately through one of two columns filled with sepharose-coupled polyclonal sheep antibodies to human immunoglobulins (Ig-Therasorb⁰⁰), whereas the other column is regenerated. Each cycle has a duration of 15 min. Three patients with high titer factor VIII antibodies (one hemophiliac and 2 with spontaneous antibodies; titers 29, 132, and 313 BU/ml, respectively) were treated. The average reduction of the antibody titer was 76.1 ± 17.2% per session. In each patient 4 sessions were necessary to reduce the antibody titer to < 1 BU/ml. The mean processed plasma volume was 6731 ± 640 ml and the mean duration of each session 3.9 ± 0.7 h. Serum IgG, IgA and IgM levels decreased by 75.3 ± 11.9%, 62.9 ± 19.1%, and 54.8 ± 23.8% respectively. The procedure was tolerated without any side effects. Thus, rapid elimination of factor VIII inhibitors can be achieved with antibody-based immunoadsorption, which can be lifesaving in some cases. This promising method should be evaluated in a larger number of patients.

• References

• 1 Briët E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, Ljung R, Rocino A, Addiego J, Lorenzo JI, Pabinger I. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products Thromb Haemost 1994; 72: 162-164
• 2 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-203
• 3 Hoyer LW, Gawryl MS, de la Fuente B. Immunochemical characterization of factor VIII inhibitors. In: Factor VIII inhibitors. Hoyer LeonW. ed. A. R. Liss Inc; New York: 1983. pp 73-85
• 4 Glueck HI, Hong R. A circulating anticoagulant in ylA-multiple myeloma: Its modification by penicillin. J Clin Invest 1965; 44: 1866-1881
• 5 Nilsson IM, Bemtorp E, Freiburghaus C. Treatment of patients with factor VIII and IX inhibitors. Thromb Haemost 1993; 70: 56-59
• 6 Francesconi M, Korninger C, Thaler E, Niessner H, Hocker P, Lechner K. Plasmapheresis: its value in the management of patients with antibodies to factor VIII. Haemostasis 1982; 11: 79-85
• 7 Nilsson IM, Jonsson S, Sundqvist SB, Ahlberg A, Bergentz SE. A procedure for removing high titer antibodies by extracorporeal protein A sepharose adsorption in hemophilia. Blood 1981; 58: 38-42
• 8 Nilsson IM, Sundqvist SB, Freiburghaus C. Extracorporeal protein A sepharose and specific affinity chromatography for removal of antibodies. In: Factor VIII inhibitors. Hoyer LeonW. ed. A. R. Liss Inc; New York: 1983. pp 225-241
• 9 Freedman J, Semple JW, Teitel J, Stewart K, Garvey B. Clinical and immunologic effects of staphylococcal protein A immunoadsorption therapy for inhibitor to factor VIII. Transfus Sci 1992; 13: 223-232
• 10 DuMoulin A, Muller-Derlich J, Bieber F, Richter WO, Frei U, Muller R, Spaethe R. Antibody Based Immunoadsorption as a Therapeutic Means. Blood Purif 1993; 11: 145-149
• 11 Graninger W, Druml W, Derfler K. IgG-apheresis in severe life-threatening lupus erythematosus. Manuscript in preparation.
• 12 Du Moulin A. LDL immunoapheresis technique. In: Gotto AM, Mancini M, Richter WO, Schwandt P. ed. Hypercholesterolemia in the prevention of coronary heart disease-2. In: Proc 2nd Int Symp, Munich. 1989. Karger, Basel; Swizerland: 1990. pp 170-174
• 13 Derfler K, Swoboda K, Hirschl MM, Gottsauner-Wolf M, Steger G, Sunder-Plassmann G, Widhalm K. Comparison of plasmaseparation and immunospecific LDL elimination in severe hypercholesterolemia. Int J Artificial Organs 1992; 15: 307-308
• 14 Richter WO, Jacob BG, Ritter MM, Siihler K, Viemeisel K, Schwandt P. Three year treatment of familial heterozygous hypercholesterolemia by extracorporeal low density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 1993; 42: 888-894
• 15 Derfler K, Druml W, Mayr W, Muhlbacher F, Jansen M, Sauter T, Horl W. Combination of IgG columns and IgG iv. in the downmodulation of cytotoxic anti-HLA antibodies and autoantibodies In: Congress of immunoglobulines intravenous - IgG iv: Current status of clinical application and research topics. Biotech Group - Hyland Division, Lissabon; Portugal: 1993. pp 15-16
• 16 Kaspar CK. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872
• 17 Nilsson IM, Bemtorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 47-50
• 18 Green D, Rademaker AW, Briët E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70: 753-757
• 19 Snyder HW, Cochran SK, Balint JP, Bertram JH, Mittelman A, Guthrie TH, Jones FR. Experience with protein A - immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood 1992; 79: 2237-2245
• 20 Christie DJ, Howe RB, Lennon SS, Sauro SC. Treatment of refractoriness to platelet transfusion by protein A column therapy. Transfusion 1993; 33: 234-242
• 21 Käbisch A, Kroll H, Wedi B, Kiefel V, Pralle H, Miiller-Eckhardt C. Severe adverse effects of protein A immunoadsorption. Lancet 1994; 343: 116